Blackstone Life Sciences and Anthos Therapeutics, Inc., a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the treatment of cardiometabolic diseases, announces that Novartis has completed its acquisition of Anthos Therapeutics in a transaction valued at up to $3.1 billion. Anthos was founded by Blackstone Life Sciences and Novartis in 2019 with the exclusive global rights from Novartis to develop, manufacture, and commercialize abelacimab, a novel Factor XI inhibitor that originated at Novartis.
Read the full article: Blackstone Life Sciences and Anthos Therapeutics Announce Novartis Has Completed the Acquisition of Anthos Therapeutics in a Deal Valued at up to $3.1B, with $925M Paid Upfront //
Source: https://www.businesswire.com/news/home/20250403148958/en/Blackstone-Life-Sciences-and-Anthos-Therapeutics-Announce-Novartis-has-Completed-the-Acquisition-of-Anthos-Therapeutics-in-a-Deal-Valued-at-up-to-%243.1B-with-%24925M-Paid-Upfront